Viral And Immune Factors That Influence Recovery Or Progression Of Hepatitis C

影响丙型肝炎恢复或进展的病毒和免疫因素

• 批准号: 10020733
• 负责人: Harvey Klein
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10020733
• 关键词: Acute Hepatitis C; Antibodies; Antibody Response; B-Lymphocytes; Blood donor; CCL2 gene; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; Chronic Disease; Chronic Hepatitis C; Containment; Disease Outcome; Escape Mutant; Evolution; Fibrosis; Genotype; Goals; Helper-Inducer T-Lymphocyte; Hepatitis; Hepatitis C; Hepatitis C virus; Heterogeneity; Immune; Immune response; Immune system; Immunologic Factors; Immunologics; Impairment; Indolent; Infection; Interferons; Lead; Link; Measures; Mediating; MicroRNAs; Mutation; Natural History; Outcome; Patients; Population; Publishing; Recovery; Science; Specimen; Testing; Time; Variant; Viral; Viral Antigens; Viral Load result; Virus; acute infection; cancer cell; cell mediated immune response; chronic infection; chronic liver disease; cohort; cytokine; cytotoxic; neutralizing antibody; outcome prediction; predictive marker; pressure; prospective; response; virology

Approximately 15 percent of patients recover from hepatitis C virus (HCV) infection while 85 percent become persistently infected with various degrees of associated chronic liver disease. In this study, comparisons will be made between patients who rapidly recover, those who have delayed recovery, those with persistent infection and stable chronic disease and those with rapidly progressive, fatal infection. The parameters measured will be viral burden (initially and over time), HCV genotype, the number of viral quasi-species (extent of viral heterogeneity) at the time of infection and subsequently, neutralizing antibody responses and, T-cell helper, proliferative and cytotoxic responses. The goal is to determine if any of these parameters can predict outcome. Studies to date have shown no correlation with genotype since the population is fairly homogeneous for HCV genotype 1. However, there does appear to be a correlation between viral quasi-species and disease outcome. Using rare specimens obtained during the first 16 weeks of HCV infection, we have measured the mean Hamming distance that reflects the extent of viral diversity (the degree of sequence divergence within the viral quasi-species). We have found that the mean Hamming distance 12 to 16 weeks after the onset of acute infection predicts whether the patient will recover from HCV infection or develop persistent infection and chronic liver disease. Patients who recover have a declining Hamming distance as antibody to HCV develops, signifying immunologic containment and then clearance of the virus. In contrast, the majority of patients demonstrate an increased mean hamming distance as antibody appears. This suggests that if the immune response is not sufficient to clear the virus, it paradoxically exerts immune pressure that results in mutations (escape variants) that lead to persistent infection. Interestingly, patients with fulminant hepatitis have a very low degree of viral diversity because they succumb to the infection before the immune system can clear the virus or exert immune pressure. This study has been published on Science in 2000(The outcome of acute hepatitis C predicted by the evolution of the viral quasi-species; Science 288:339-344).In ongoing studies, we are measuring the viral quasi-species throughout the long-term course of HCV infection and the relation of the quasispecies other parameters to the outcome of HCV infection. Thus far, studies have shown that patients with chronic HCV infection have impaired CD4 and CD8 cell responses to all HCV antigens compared to patients who recover from acute HCV infection.We have also found that neutralizing antibodies do not correlate with recovery from acute HCV infection, but rather continue to increase in strength and breath of activity over the course of chronic infection. Despite these antibodies, escape mutants continue to evade the immune response. Most recently, we have compared patients who have severe, rapidly progressive hepatitis C to those who have a stable indolent course. We found that patients with rapid progression have a delayed or impaired immunologic response to HCV, an inability to reduice viral load early in infection, a greater degree of viral diversity, a diminished interferon response and, importantly, an early and sustained elevation of the pro-fibrogenic cytokine, MCP-1. We are now testing in a larger cohort wheteher MCP-1 could serve as a predictive marker of severe fibrosis in patients with chronic hepatitis C. Ongoing studies are looking for other cytokines or micro RNAs that might predict fibrosis progression. In this regard we have shown that the miRNA, Let-7, is a predictive marker of fibrosis progression.

大约 15% 的患者从丙型肝炎病毒 (HCV) 感染中康复，而 85% 的患者则持续感染不同程度的相关慢性肝病。在这项研究中，将对快速康复的患者、延迟康复的患者、持续感染且慢性疾病稳定的患者以及快速进展、致命感染的患者进行比较。测量的参数包括病毒负荷（初始和随时间变化）、HCV 基因型、感染时的病毒准种数量（病毒异质性程度）以及随后的中和抗体反应以及 T 细胞辅助反应、增殖和细胞毒性反应。目标是确定这些参数中的任何一个是否可以预测结果。迄今为止的研究表明，由于 HCV 基因型 1 的人群相当同质，因此与基因型没有相关性。然而，病毒准种与疾病结果之间似乎确实存在相关性。使用 HCV 感染前 16 周期间获得的稀有样本，我们测量了反映病毒多样性程度（病毒准种内序列分歧程度）的平均汉明距离。我们发现，急性感染发作后12至16周的平均汉明距离可以预测患者是否会从HCV感染中恢复或发展为持续感染和慢性肝病。随着 HCV 抗体的产生，康复患者的汉明距离逐渐下降，这意味着病毒被免疫遏制，然后被清除。相反，随着抗体的出现，大多数患者表现出平均汉明距离增加。这表明，如果免疫反应不足以清除病毒，它就会矛盾地施加免疫压力，导致突变（逃逸变体），从而导致持续感染。有趣的是，暴发性肝炎患者的病毒多样性非常低，因为他们在免疫系统清除病毒或施加免疫压力之前就死于感染。该研究已于2000年发表在《Science》杂志上（《病毒准种进化预测急性丙型肝炎的结果；Science 288:339-344》）。在正在进行的研究中，我们正在测量HCV感染长期过程中的病毒准种以及准种其他参数与HCV感染结果的关系。 迄今为止，研究表明，与从急性HCV感染中恢复的患者相比，慢性HCV感染患者的CD4和CD8细胞对所有HCV抗原的反应均受损。我们还发现中和抗体与急性HCV感染的恢复并不相关，而是在慢性感染过程中持续增加活动的强度和呼吸。尽管有这些抗体，逃逸突变体仍继续逃避免疫反应。最近，我们将患有严重、快速进展的丙型肝炎的患者与具有稳定惰性病程的患者进行了比较。我们发现，快速进展的患者对 HCV 的免疫反应延迟或受损，无法在感染早期减少病毒载量，病毒多样性更大，干扰素反应减弱，重要的是，促纤维化细胞因子 MCP-1 早期持续升高。我们现在正在更大的队列中测试 MCP-1 是否可以作为慢性丙型肝炎患者严重纤维化的预测标志物。正在进行的研究正在寻找可能预测纤维化进展的其他细胞因子或微小 RNA。在这方面，我们已经证明 miRNA Let-7 是纤维化进展的预测标记。